Author Archives: admin


Human Embryonic Stem Cells (HESC) Market Analysis and Growth Forecast by Applications, Types and Competitors to … – DailyNewsKs

Human Embryonic Stem Cells (HESC) Market research report is a professional and in-depth study on the current state. The Human Embryonic Stem Cells (HESC) Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regional development status.

Browse more detail information about Human Embryonic Stem Cells (HESC) Market at:http://www.360marketupdates.com/10613660

Next part of the Human Embryonic Stem Cells (HESC) Market sheds light on the production, production plants, their capacities, global production and revenue are studied. Also, the Human Embryonic Stem Cells (HESC) Market growth in various regions and R&D status are also covered.

Human Embryonic Stem Cells (HESC) Market report key players-Astellas Pharma Inc/ Ocata Therapeutics, STEMCELL Technologies, BIOTIME, INC, Thermo Fisher Scientific, CellGenix, ESI BIO, PromoCell, Lonza, Kite Pharma, Cynata, Sumanas, LifeCell, Geron And Many Others

Get Sample PDF of report@ http://www.360marketupdates.com/enquiry/request-sample/10613660

Further in the report, Human Embryonic Stem Cells (HESC) Market is examined for price, cost and gross revenue. These three points are analysed for types, companies and regions. In prolongation with this data sale price for various types, applications and region is also included.

Human Embryonic Stem Cells (HESC) Market split by Product Type-Adult Sources, Fetal Sources Human Embryonic Stem Cells (HESC) Market split by Application Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing Human Embryonic Stem Cells (HESC) Market Segment by Regions-North America, China, Europe, Southeast Asia, Japan, India

With the help of supply and consumption data, gap between these two is also explained. To provide information on competitive landscape, this report includes detailed profiles of Human Embryonic Stem Cells (HESC) Market key players.

Have any query? Ask our expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10613660

Other Major Topics Covered in Human Embryonic Stem Cells (HESC) market report are as follows:

Marketing Strategy Analysis, Distributors/Traders: Marketing Channel, Direct Marketing, Indirect Marketing, Marketing Channel Development Trend, Market Positioning, Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List. Market Effect Factors Analysis: Technology Progress/Risk; Substitutes Threat; Technology Progress in Related Industry; Consumer Needs/Customer; reference Change; Economic/Political Environmental Change. Global Human Embryonic Stem Cells (HESC) Market Forecast 2017-2021: Global Human Embryonic Stem Cells (HESC) Capacity, Production, Revenue Forecast 2017-2021; Global Human Embryonic Stem Cells (HESC) Production, Consumption Forecast by Regions 2017-2021; Global Human Embryonic Stem Cells (HESC) Production Forecast by Type 2017-2021; Global Human Embryonic Stem Cells (HESC) Consumption Forecast by Application 2017-2021; Human Embryonic Stem Cells (HESC) Price Forecast 2017-2021.

In this Human Embryonic Stem Cells (HESC) Market analysis, traders and distributors analysis is given along with contact details. For material and equipment suppliers also, contact details are given. New investment feasibility analysis is included in the report.

Continue reading here:
Human Embryonic Stem Cells (HESC) Market Analysis and Growth Forecast by Applications, Types and Competitors to ... - DailyNewsKs

Beta Cell Growth Finding May Lead to Improved Therapies for Diabetics – Genetic Engineering & Biotechnology News (press release)

Scientists at theUniversity of California San Diego School of Medicine usedsingle-cell RNA sequencing to map out pathways that regulate cell growth that could be exploited to trick them to regenerate.

Pancreatic cells help maintain normal blood glucose levels by producing insulin, the master regulator of energy (glucose). Impairment and the loss of cells interrupts insulin production, leading to types 1 and 2 diabetes.The team's study ("Pseudotemporal Ordering of Single Cells Reveals Metabolic Control of Postnatal Cell Proliferation") is published in Cell Metabolism.

"If we can find a drug that makes cells grow, it could improve blood sugar levels in people with diabetes," said Maike Sander, M.D., professor in the Department of Pediatrics and Cellular and Molecular Medicine at UC San Diego School of Medicine. "These people often have residual cells, but not enough to maintain normal blood glucose levels."

The body generates cells in utero and they continue to regenerate after birth. But as people age, cell regeneration diminishes. The predominant way to grow new cells is through cell division; but cells capable of dividing are rare, compromising less than 1% of all cells. Scientists have been investigating molecular pathways that govern cell growth in hopes of finding new therapies that would help people regain blood glucose control after the onset of diabetes.

In their work, Dr. Sander's team identified the pathways that are active when cells divide, providing insight into possible drug targets. The investigators were able to profile molecular features and metabolic activity of individual cells to determine how dividing cells differ from nondividing cells.

"No one has been able to do this analysis because the 1% or less of cells that are dividing are masked by the 99% percent of cells that are not dividing," said Dr. Sander. "This in-depth characterization of individual cells in different proliferative states was enabled by newer technology. It provides a better picture of what sends cells into cell division and clues we can use to try to develop drugs to stimulate certain pathways."

Whether stimulating cells to grow will result in therapeutic interventions for diabetes is still to be seen, but this new information opens the door to find out, she added.

Originally posted here:
Beta Cell Growth Finding May Lead to Improved Therapies for Diabetics - Genetic Engineering & Biotechnology News (press release)

US Stem Cell Inc (OTCMKTS:USRM) Explodes Higher Ahead of RMAT Decision – The Oracle Dispatch

US Stem Cell Inc (OTCMKTS:USRM) is a penny player in the stem cell space that caught a massive jolt of bullish energy to start off this week. We didnt see any clear new catalyst emerge, but the move likely hooks into the companys near-term narrative, which is highly entangled with a decision of whether or not to approve the companys application to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of its MARVEL trial.

According to a press release last month, the trial had previously been placed on Inactive Status as patients were not actively being enrolled. A request was placed to the FDA to reactivate the protocol and consider the therapy for RMAT designation. We have recently heard from the FDA who has notified us that the protocol has been placed on Reactivation Status after reviewing details on the protocol and data collected on patients to date. The FDA has also notified us that they are still reviewing our submission for RMAT.

US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the bodys own healing potential, we may be able to reverse damaged tissue to normal function.

U.S. Stem Cells discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

According to company materials, US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Subscribe below and well keep you on top of whats happening before $USRM stock makes its next move.

As noted above, the stock shifted into bull mode to start this week. However, traders are scrambling to uncover the catalyst for the move.

We would say the most likely catalyst has to do with expectations surrounding its application for RMAT status with the FDA. That was apparently expected to hit as a decision sometime in May. Today marks the outset of the new month, and we may have either rumors or speculation fueling the idea that one must not wait any longer if one wants to catch the action into that catalyst the idea being, approval would seriously juice this stock higher.

Recent action has seen 33% piled on for shareholders of the company during the trailing week. This is emblematic of the stock. USRM has evidenced sudden upward volatility on many prior occasions. Whats more, the listing has benefitted from a jump in recent trading volume to the tune of 16% over what the stock has registered over the longer term.

According to the company, Thanks to the REGROW component of the Cures Act, the FDA will grant RAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease. We believe that our MyoCell product meets these requirements, as we have demonstrated clinical efficacy in both preclinical and clinical studies, including our most recent MARVEL trial publication.

Earning a current market cap value of $44.2M, USRM has a reported chunk ($271K) of cash on the books, which compares with about $3M in total current liabilities. USRM is pulling in trailing 12-month revenues of $3.1M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 66.6%. We will update the story again soon as developments transpire. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Follow this link:
US Stem Cell Inc (OTCMKTS:USRM) Explodes Higher Ahead of RMAT Decision - The Oracle Dispatch

Presidential Symposium at the American Society of Gene and Cell … – Yahoo Finance

FREMONT, Calif., May 3, 2017 /PRNewswire/ --Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that data from its AST-OPC1 clinical program for severe cervical spinal cord injury will be presented during the Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting, being held in Washington, D.C. during May 10-13, 2017.

"The ASGCT decision to include a presentation on AST-OPC1 in its Presidential Symposium signifies the ground-breaking nature of our program, and reflects the encouraging efficacy and safety data we have seen to date in patients with severe spinal cord injuries that have been treated with AST-OPC1," said Steve Cartt, President and Chief Executive Officer of Asterias. "Data will be presented from our SCiStar study demonstrating the potential of AST-OPC1 to help patients with complete paralysis regain increased arm, hand and finger function, and thus greater ability to live independently."

Jane S. Lebkowski, Ph.D., Asterias' President of R&D and Chief Scientific Officer, will be one of the presenters during the Presidential Symposium session scheduled on Friday, May 12, 2017 at 1:00pm Eastern Time. Dr. Lebkowski's presentation, titled "498 - Safety and Efficacy of Human Embryonic Stem Cell Derived Oligodendrocyte Progenitor Cells (AST-OPC1) in Patients with Subacute Cervical Spinal Cord Injury," is expected to begin at 2:15pm Eastern Time. The abstract for Dr. Lebkowski's presentation at the ASGCT meeting is available online at: http://www.abstractsonline.com/pp8/#!/4399/presentation/1996.

ASGCT is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. Its members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. Its mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease.

About the SCiStar Trial

The SCiStar trial is an open-label, single-arm trial testing three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in as many as 35 patients with sub-acute, C-5 to C-7, motor complete (AIS-A or AIS-B) cervical SCI. These individuals have essentially lost all movement below their injury site and experience severe paralysis of the upper and lower limbs. AIS-A patients have lost all motor and sensory function below their injury site, while AIS-B patients have lost all motor function but may retain some minimal sensory function below their injury site. AST-OPC1 is being administered 14 to 30 days post-injury. Patients will be followed by neurological exams and imaging procedures to assess the safety and activity of the product.

The study is being conducted at six centers in the U.S. and the company plans to increase this to up to 12 sites to accommodate the expanded patient enrollment. Clinical sites involved in the study include the Medical College of Wisconsin in Milwaukee, Shepherd Medical Center in Atlanta, University of Southern California (USC) jointly with Rancho Los Amigos National Rehabilitation Center in Los Angeles, Indiana University, Rush University Medical Center in Chicago and Santa Clara Valley Medical Center in San Jose jointly with Stanford University.

Asterias has received a Strategic Partnerships Award grant from the California Institute for Regenerative Medicine, which provides $14.3 million of non-dilutive funding for the Phase 1/2a clinical trial and other product development activities for AST-OPC1.

Additional information on the Phase 1/2a trial, including trial sites, can be found at http://www.clinicaltrials.gov, using Identifier NCT02302157, and at the SCiStar Study Website (www.SCiStar-study.com).

About AST-OPC1

AST-OPC1, an oligodendrocyte progenitor population derived from human embryonic stem cells, has been shown in animals and in vitro to have three potentially reparative functions that address the complex pathologies observed at the injury site of a spinal cord injury. These activities of AST-OPC1 include production of neurotrophic factors, stimulation of vascularization, and induction of remyelination of denuded axons, all of which are critical for survival, regrowth and conduction of nerve impulses through axons at the injury site. In preclinical animal testing, AST-OPC1 administration led to remyelination of axons, improved hindlimb and forelimb locomotor function, dramatic reductions in injury-related cavitation and significant preservation of myelinated axons traversing the injury site.

Read More

In a previous Phase 1 clinical trial, five patients with neurologically complete, thoracic spinal cord injury were administered two million AST-OPC1 cells at the spinal cord injury site 7-14 days post-injury. They also received low levels of immunosuppression for the next 60 days. Delivery of AST-OPC1 was successful in all five subjects with no serious adverse events associated with AST-OPC1. No evidence of rejection of AST-OPC1 was observed in detailed immune response monitoring of all patients. In four of the five patients, serial MRI scans indicated that reduced spinal cord cavitation may have occurred. Based on the results of this study, Asterias received clearance from FDA to progress testing of AST-OPC1 to patients with cervical spine injuries, which represents the first targeted population for registration trials.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The company's proprietary cell therapy programs are based on its pluripotent stem cell and immunotherapy platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) is undergoing continuing development by Asterias based on promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML), with current efforts focused on streamlining and modernizing the manufacturing process. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic cancer immunotherapy. The company's research partner, Cancer Research UK, plans to begin a Phase 1/2a clinical trial of AST-VAC2 in non-small cell lung cancer in 2017. Additional information about Asterias can be found at http://www.asteriasbiotherapeutics.com.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating and/or clinical research results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/presidential-symposium-at-the-american-society-of-gene-and-cell-therapy-asgct-20th-annual-meeting-will-feature-presentation-on-asterias-ast-opc1-for-spinal-cord-injury-300450272.html

Link:
Presidential Symposium at the American Society of Gene and Cell ... - Yahoo Finance

Cell Therapy Company Joins Forces with Biotech in New Transplantation Research Alliance – Pharmaceutical Processing

Be The Match BioTherapies announces collaboration agreement with Magenta Therapeutics.

MINNEAPOLIS, May 2, 2017 Be The Match BioTherapiesSM, an organization offering solutions for delivering autologous and allogeneic cellular therapies, today announced that it has entered into a strategic partnership with Magenta Therapeutics, a biotechnology company developing therapies to improve and expand the use of curative stem cell transplantation. The collaboration is intended to support efforts to improve transplant outcomes and expand the application of stem cell transplantation into disease indications that include autoimmunity, serious inherited immune and metabolic disorders, blood defects and blood cancers. Be The Match BioTherapies also announced today that it is participating in Magentas Series B financing round, its first equity investment as an organization.

Under the terms of the collaboration agreement, Be The Match BioTherapies and Magenta will explore opportunities to work together across Magentas discovery, clinical development and product delivery efforts. The collaboration leverages a wide range of Be The Match BioTherapies research assets and services, including the National Marrow Donor Program(NMDP)/Be The Match marrow registry, the largest in the world with nearly 16 million volunteer marrow donors. Magenta may also collaborate with Be The Match BioTherapies in the design of clinical trials and of its cell therapy delivery platform and services.

Partnering with Magenta in its efforts to revolutionize the current state of stem cell transplantation aligns with our core mission to help organizations deliver cellular therapies that save more lives and improve the quality of life for patients, said Amy Ronneberg, President of Be The Match BioTherapies. Our collaboration with Magenta exemplifies how cell and gene therapy companies can benefit from our robust network of products and services regardless of where they are in the development life cycle. We look forward to lending our expertise in cellular therapy and leveraging our deep-rooted relationships, partnerships and global infrastructure to support the development of powerful treatment options with great potential to improve patient outcomes in a range of disease areas.

Jason Gardner, D. Phil., Chief Executive Officer, President, and Cofounder of Magenta, added: We believe that Be The Match BioTherapies extensive experience and network in stem cell transplant medicine, coupled with Magentas work in patient conditioning and stem cell harvesting and growth, could accelerate our development path and ability to positively impact patients lives.

Be The Match BioTherapies launched in 2016 as a subsidiary of NMDP/Be The Match, the national organization with a 30-year history of connecting patients with their donor match for a life-saving bone marrow or umbilical cord blood transplant. As experts in providing services and expertise to organizations pursuing life-saving treatments in the cellular therapy space, Be The Match BioTherapies aims to help critically ill patients who can benefit from these treatments.

(Source:Business Wire)

Follow us onTwitterandFacebookfor updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Excerpt from:
Cell Therapy Company Joins Forces with Biotech in New Transplantation Research Alliance - Pharmaceutical Processing

CIRM California’s stem cell research funding agency to lose … – San Francisco Business Times


Xconomy
CIRM California's stem cell research funding agency to lose ...
San Francisco Business Times
Randy Mills, who came in to right California's semi-public stem cell research funding agency, is leaving to head the National Marrow Donor Program. Mills three ...
CA Stem Cell Agency Chief Randy Mills to Leave After Three Years ...Xconomy
Be the Match names CEO to succeed retiring Chell - Minneapolis ...Minneapolis / St. Paul Business Journal

all 4 news articles »

Excerpt from:
CIRM California's stem cell research funding agency to lose ... - San Francisco Business Times

StemCONN Symposium Shows Connecticut is Leader in Stem Cell Research – Wesleyan Connection (blog)


Wesleyan Connection (blog)
StemCONN Symposium Shows Connecticut is Leader in Stem Cell Research
Wesleyan Connection (blog)
Stem cell research continues to be an exciting and fast-paced field with new discoveries fueling prospects for new therapies based on regenerative medicine for a range of debilitating medical conditions, and Connecticut is at the leading edge of this ...

Read more here:
StemCONN Symposium Shows Connecticut is Leader in Stem Cell Research - Wesleyan Connection (blog)

Triggering Stem Cells for Accelerated Healing – Anti Aging News

Recent research, led by assistant professor of stem cell biology and regenerative medicine at the University of South Carolina Joseph T. Rodgers, has found a way to increase the bodys ability to heal after injury. The study was published in the scientific journal Cell Reports.

The research was funded by grants from the National Institutes of Health. Funding was also secured from the Donald E. and Delia B. Baxter Foundation, Glenn Foundation for Medical Research, and the Department of Veterans Affairs. The study was co-sponsored by the Department of Neurology and Neurological Sciences at Stanford. Clinical Research

In previous research, Rodgers proved that adult stem cells enter an alert state when the body sustains an injury. Alert stem cells have greater ability to heal and repair damaged tissues.

Rodgers theorized that blood from an injured person could produce a state of alert in another persons stem cells. Using lab mice, he and his team injected healthy mice with blood from their injured counterparts. The stem cells of the healthy mice were observed to adopt the state of alert.

The team was able to expose the chemical mechanism used to signal cells to enter an alert state as the enzyme Hepatocyte Growth Factor Activator (HGFA). HGFA is always present in the bloodstream but does not activate until the body experiences an injury. Once an injury occurs, the enzyme signals adult stem cells to enter the alert state.

Implications for Repair Response in the Injured Body

Once these findings were discovered, Rodgers team decided to investigate what would happen if an injury was sustained while the adult stem cells were already in a state of alert.

HGFA was injected into healthy mice. Several days later, the mice were given skin or muscle injuries. Test subjects were observed to heal faster, regrow missing fur, and return to running on exercise wheels sooner.

This research supports the idea that the presence of HGFA in the bloodstream prepares the body to respond more quickly and efficiently to injury. Similar to the way vaccines prepare the body to fight specific diseases, HGFA readies cells to respond to tissue damage.

Future Applications

In the future, people may be able to use HGFA before they engage in activities that could result in injury, like sports, surgery, or battle. HGFA could also be used in a therapeutic capacity for those with compromised healing abilities, like diabetes patients or senior citizens.

Forthcoming studies will explore how HGFA affects declines in the ability to heal, and how to use it to restore normal healing abilities.

Excerpt from:
Triggering Stem Cells for Accelerated Healing - Anti Aging News

Auto pioneer’s family turns tragedy into discovery with $5 million commitment to bipolar research – Medical Xpress

May 1, 2017 Stem cells derived from skin cells donated by people with and without bipolar disorder are helping researchers make discoveries about the condition at the most basic level. Credit: University of Michigan

Fifty years ago this spring, entrepreneur Heinz Prechter moved his company to Detroit, to answer car buyers' fast-growing demand for sunroofs. But even as his products brought light into more than a million vehicles, he fought darkness in his own life.

He struggled to keep his bipolar disorder hidden, until his suicide in July 2001 shocked the automotive industry.

Heinz's wife, Waltraud "Wally" Prechter, resolved to fight the stigma that led her husband to hide his mental illness, and to address the lack of scientific understanding about the condition and how best to treat it. She channeled her energy into helping the University of Michigan Depression Center do both, by donating and raising money for a U-M bipolar research fund in her husband's name.

Today, U-M named its entire bipolar disorder research program for Heinz Prechter, in honor of a new gift commitment of up to $5 million by the World Heritage Foundation - Prechter Family Fund.

But the gift comes with a challenge to others who care about bipolar disorder: The Prechter family will match every dollar given to U-M bipolar disease research up to $5 million. This will double the value of every donation, and the Prechter family gift will be available to researchers faster, if others step in to support the cause.

Once the challenge is met, the Prechter family's total giving to U-M bipolar research since Heinz Prechter's death will be well over $10 million. Philanthropic gifts, including individual, foundation and corporate gifts, are critical to the effort and account for more than half of the research funding in any given year. The Prechter family set up this gift as a match to encourage more philanthropic support of research into bipolar disorder.

"I think that if you canif you truly believe in somethingyou owe it to yourself to help, to give, and to make a difference. Because ultimately, that is all you leave behind," says Wally Prechter.

Says U-M president Mark Schlissel, M.D., Ph.D., "I deeply appreciate Wally Prechter's commitment to advancing bipolar disease research that will give hope to millions of people around the world. The Heinz C. Prechter Bipolar Research Program will enhance the University of Michigan's longstanding research initiatives and drive new medical discoveries to combat this devastating disorder."

Building new innovation and advancing bipolar science

"When we lost Heinz to his disease, it took Wally's bravery and generosity to help us create incredible good out of such a tragic loss," says John Greden, M.D., who was working with Heinz and Wally Prechter to create the U-M Depression Center at the time of Heinz's death. Greden is the Depression Center's director and a professor of psychiatry at Michigan Medicine, the U-M academic medical center.

"Without Wally Prechter's leadership over the past decade, we would not have been able to develop the world's first bipolar-specific stem cell lines, discover new genetic links, explore environmental factors or bring experts worldwide together as we have," says Melvin McInnis, M.D., who is the Thomas B. and Nancy Upjohn Woodworth Professor of Bipolar Disorder, professor of psychiatry, and director of the newly named Heinz C. Prechter Bipolar Research Program.

The Prechter family is committed to increasing scientific understanding and treatment options that will enable people with bipolar disorder to lead healthy and productive lives. The new gift will grow the endowment that provides for the continuation of the Prechter Longitudinal Study of Bipolar Disorder, which has been ongoing for 11 years.

The Longitudinal Study allows researchers to track symptoms, response to treatment and overall health over time like never before. Already, more than 1,200 dedicated individuals have partnered with the research team to track personal and medical information for this long-term study.

"Our participants are the real heroes," says Wally Prechter. "The goal of the Prechter Program is to identify effective solutions for people with bipolar disorder."

Volunteers can also donate samples of their blood, giving scientists the chance to study tiny differences in DNA that may play a role in how the disorder develops, why it runs in families, how it affects people over time and what makes people vary in their response to treatment.

The "bank" of DNA from hundreds of research participants over the last decade is called the Heinz C. Prechter Bipolar Genetics Repository, and it is the nation's largest privately funded bipolar genetics repository.

"We look forward to fueling new discoveries, and involving hundreds more people with bipolar and their families in the search for better treatments. The new funding, from the Prechters and others who believe in our work, will allow us to accelerate our pace of discovery," says McInnis.

The Heinz C. Prechter Bipolar Research Program will be the umbrella program over the Longitudinal Study of Bipolar Disorder and other bipolar research studies.

About bipolar disorder

Bipolar disorder is a devastating, chronic mental illness with recurring episodes of mania (highs) and depression (lows). The illness causes unusual and dramatic shifts in mood, energy and behavior. Presently, 30 percent of individuals with bipolar disorder attempt suicide during their lives, and 20 percent die by suicide.

Although the direct cause of bipolar disorder is unclear, it has long been understood that genetic, biochemical and environmental factors play a role. Bipolar disorder runs in families, tends to recur throughout the life span and is affected by genes and life experiences.

Explore further: Childhood trauma associated with worse impulse control in adulthood

The scars of childhood abuse and neglect affect adults' brains for decades to come - including their ability to process and act on information both quickly and accurately, new research suggests.

Levels of residual morbidity in mood disorder patients followed up long-term under community conditions of treatment are remarkably high. Both unipolar major depressive disorder and bipolar disorder patients tend to be ill ...

What makes a person bipolar, prone to manic highs and deep, depressed lows? Why does bipolar disorder run so strongly in families, even though no single gene is to blame? And why is it so hard to find new treatments for a ...

People with the highest risk of developing bipolar disorder exhibit weak connections in the emotional areas of the brain, a world-first Australian study shows.

Every day, millions of people with bipolar disorder take medicines that help keep them from swinging into manic or depressed moods. But just how these drugs produce their effects is still a mystery.

Poor sleep is associated with negative mood in women with bipolar disorder, according to researchers at Penn State College of Medicine and University of Michigan Medical School.

College students who participated in a self-administered intervention prompting them to reflect about their use of classroom resources had final grades that were higher than their peers, according to new findings published ...

Selecting the antidepressant that will be most effective for a specific patient suffering from depression can be a "try and try again" process. Examining new personalized and precision psychiatry approaches, a new study in ...

Just 10 minutes of daily mindful mediation can help prevent your mind from wandering and is particularly effective if you tend to have repetitive, anxious thoughts, according to a study from the University of Waterloo.

Worry - it does a body good. And, the mind as well. A new paper by Kate Sweeny, psychology professor at the University of California, Riverside, argues there's an upside to worrying.

An analysis just published online has broken new ground by finding gender differences in both symptoms and diagnoses of depression appearing at age 12.

Turning down that delicious piece of chocolate cake. Resisting the temptation to buy clothes that we don't need. If we want to watch our weight and save our pennies, these enticements demand that we exercise some degree of ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Auto pioneer's family turns tragedy into discovery with $5 million commitment to bipolar research - Medical Xpress

Protein that kick-starts gene expression in developing embryos. – Science Daily

Protein that kick-starts gene expression in developing embryos.
Science Daily
Next, they looked at mouse embryonic stem cells, which contain the mouse version of the DUX4 gene (called simply DUX). When in culture, a small fraction of these cells exhibit a any given time the gene expression pattern of 2-cell stage embryos, before ...

and more »

View post:
Protein that kick-starts gene expression in developing embryos. - Science Daily